Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

The Analyst Landscape: 6 Takes On Axsome Therapeutics ↗

January 16, 2024

Via Benzinga

January 04, 2024

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.

Analyst Expectations for Axsome Therapeutics's Future ↗

November 07, 2023

Via Benzinga

Earnings Scheduled For November 6, 2023 ↗

November 06, 2023

Via Benzinga

3 Stocks That Have Turned $50,000 Into More Than $500,000 in Just 5 Years ↗

January 03, 2024

Is it too late to invest in these fast-growing stocks?

The types of innovative drugs these companies develop are always in high demand.

2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

January 02, 2024

Investors could enjoy an especially happy new year with these great stocks.

Prediction: These 3 Stocks Will Soar in 2024 ↗

January 01, 2024

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting

December 11, 2023

These stocks could be just the ticket for investors seeking strong growth.

3 Unstoppable Stocks to Buy Right Now ↗

December 10, 2023

Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

December 07, 2023

AXSM DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM

November 27, 2023

From The Rosen Law Firm PA

AXSM FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM

November 25, 2023

WHY: NEW YORK, NY - (NewMediaWire) - November 25, 2023 - Rosen Law Firm, a global investor rights law firm, reminds investors of the common stock of Axsome Therapeutics, Inc. (“Axsome”) (NASDAQ: AXSM)...

Via NewMediaWire

Topics Lawsuit

AXSM FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM

November 24, 2023

From The Rosen Law Firm PA

Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7

November 22, 2023

Many biotech stocks offer exciting long-term growth prospects.

3 Biotech Stocks That Could Be Millionaire Makers ↗

November 22, 2023

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM

November 21, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

November 21, 2023

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM

November 18, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM

November 17, 2023

From The Rosen Law Firm PA

Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers – AXSM

November 16, 2023

From The Rosen Law Firm, P.A.

Via Business Wire

3 Growth Stocks to Buy Right Now Without Any Hesitation ↗

November 11, 2023

Investors shouldn't have to deliberate for too long about these great stocks.

3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest Rates ↗

November 09, 2023

Can these promising growth stocks continue rising in value?

Axsome's Strategy on Payer Coverage Slowly Pays Off, Depression Drug Sales Show Growth ↗

Topics Economy

November 06, 2023

Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q3 revenues of $57.8 million, up 244% Y/Y, beating the consensus of $54.75 m

Via Benzinga

Axsome Therapeutics (AXSM) Q3 2023 Earnings Call Transcript ↗

November 06, 2023

AXSM earnings call for the period ending September 30, 2023.

Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Topics Earnings

November 06, 2023

Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023

November 02, 2023

Axsome’s headquarters to be lit in teal as part of the Alzheimer’s Foundation of America awareness campaign

Axsome Therapeutics to Present at Upcoming Investor Conferences

October 31, 2023